Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Houston, Texas 77030


For patients with relapsed and refractory aggressive non-Hodgkin's lymphoma


INCLUSION: - Bidimensionally measurable current/refractory aggressive NHL (Diffuse lg cell, diffuse mixed cell, follicular lg non-cleaved, immunoblastic, Ki-1+ALCL, peripheral T-cell lymphoma, mantle cell lymphoma & transformed lymphoma.) - No more than 3 prior treatment regimens. No anti-lymphoma therapy within the past 3 weeks. - Not be eligible for treatment of a higher priority. - Performance status <2 Zubrod, > 60 Karnofsky. - Good marrow reserve: ANC>1.5 x 10(9)/L, platelets > 100 x 10(9)/L. - Bilirubin <1.5mg/dL, SGOT, SGPT < 2 x normal values. - Serum creatinine < 1.8 mg/dL. - Age > 18 yrs. - Signed informed consent. - Life expectancy of > 12 weeks. - No prior Taxane (paclitaxel or docetaxel), topotecan, or CPT-11. - No prior stem cell or bone marrow transplantation. - No prior second malignancies except for basal cell carcinoma of the skin. EXCLUSION: - Active or prior history of CNS lymphoma. - Serious intercurrent medical illnesses requiring hospitalization. - History of primary/secondary immunodeficiency (other than related to the malignant lymphoma because treatment is dependent on a functional immune system) or patients taking immunosuppressive drugs (systemic corticosteroids). - Prior exposure to Filgrastim-SD/01. - Women who are pregnant or lactating. - Participation in another clinical trial. - Positive HIV antibody. - History of prior sensitivity to E. coli derived products (such as filgrastim/neupogen).



Primary Contact:

Principal Investigator
Anas Younes, MD
UT MD Anderson Cancer Center

Backup Contact:


Location Contact:

Houston, Texas 77030
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.